Introduction: Interferon-β (IFNß) is the first-line treatment for relapsing-remitting multiple sclerosis. Myxovirus resistance protein A (MxA) is a marker of IFNß bioactivity, which may be reduced by neutralizing antibodies (NAbs) against IFNß. The aim of the study was to analyze the kinetics of MxA mRNA expression during long-term IFNβ treatment and assess its predictive value.
Methods: A prospective, observational, open-label, non-randomized study was designed in multiple sclerosis patients starting IFNß treatment. MxA mRNA was assessed prior to initiation of IFNß therapy and every three months subsequently. NAbs were assessed every six months. Assessment of relapses was scheduled every three months during 24 months of follow up. The disease activity was correlated to the pretreatment baseline MxA mRNA value. In NAb negative patients, clinical status was correlated to MxA mRNA values.
Results: 119 patients were consecutively enrolled and 107 were included in the final analysis. There was no correlation of MxA mRNA expression levels between baseline and month three. Using survival analysis, none of the selected baseline MxA mRNA cut off points allowed prediction of time to first relapse on the treatment. In NAb negative patients, mean MxA mRNA levels did not significantly differ in patients irrespective of relapse status.
Conclusion: Baseline MxA mRNA does not predict the response to IFNß treatment or the clinical status of the disease and the level of MxA mRNA does not correlate with disease activity in NAb negative patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5231341 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0169957 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
[Myxovirus resistance protein A (MxA) induces the expression of interferon-stimulated genes in HepG2 cells by enhancing the activity of the interferon-stimulated response element (ISRE)].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
August 2024
The Second Hospital of Anhui Medical University, Hefei 230601, China.
Article Synopsis
- - The study investigates the role of Myxovirus resistance protein A (MxA) on the JAK/STAT signaling pathway in HepG2 cells, focusing on the localization and expression of MxA through various biochemical methods.
- - Results showed that MxA is primarily localized in the cytoplasm, and while knocking down MxA does not impact STAT protein levels, it significantly lowers antiviral proteins PKR and OAS expression.
- - Overexpressing MxA increases ISRE activity and boosts PKR and OAS levels, indicating that MxA promotes antiviral protein expression by enhancing the JAK/STAT pathway's activity, though this effect is blocked in HepG2.2.15 cells.
Characterization of the impact of dietary immunostimulant CpG on the expression of mRNA biomarkers involved in the immune responses in Atlantic salmon (Salmo salar).
Fish Shellfish Immunol
October 2024
Department of Ocean Sciences, Memorial University of Newfoundland, St. John's, NL, A1C 5S7, Canada. Electronic address:
Infectious diseases have significantly impacted Atlantic salmon aquaculture worldwide. Modulating fish immunity with immunostimulant-containing functional feeds could be an effective strategy in mitigating disease problems. Previously, we characterized the impact of polyriboinosinic polyribocytidylic acid (pIC) and formalin-killed typical Aeromonas salmonicida bacterin on miRNA expression in Atlantic salmon fed a commercial diet with and without immunostimulant CpG.
View Article and Find Full Text PDFAge-related transcript changes in type I interferon signaling in children and adolescents with long COVID.
Eur J Immunol
May 2024
Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.
SARS-CoV-2 typically causes mild symptoms in children, but evidence suggests that persistent immunopathological changes may lead to long COVID (LC). To explore the interplay between LC and innate immunity, we assessed the type I interferon (IFN-I) response in children and adolescents with LC symptoms (LC; n = 28). This was compared with age-matched SARS-CoV-2 recovered participants without LC symptoms (MC; n = 28) and healthy controls (HC; n = 18).
View Article and Find Full Text PDFActivation of Toll-like receptor 3 inhibits HIV infection of human iPSC-derived microglia.
J Med Virol
November 2023
Department of Pathology and Laboratory Medicine, Temple University LewisKatz School of Medicine, Philadelphia, Pennsylvania, USA.
As a key immune cell in the brain, microglia are essential for protecting the central nervous system (CNS) from viral infections, including HIV. Microglia possess functional Toll-like receptor 3 (TLR3), a key viral sensor for activating interferon (IFN) signaling pathway-mediated antiviral immunity. We, therefore, studied the effect of poly (I:C), a synthetic ligand of TLR3, on the activation of the intracellular innate immunity against HIV in human iPSC-derived microglia (iMg).
View Article and Find Full Text PDFCOVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.
Vaccine
June 2023
Infection and Immunity, Institute of Biomedicine, University of Turku, 20520 Turku, Finland; Turku University Hospital, Clinical Microbiology, 20520 Turku, Finland. Electronic address:
Background: During the COVID-19 pandemic multiple vaccines were rapidly developed and widely used throughout the world. At present there is very little information on COVID-19 vaccine interactions with primary human immune cells such as peripheral blood mononuclear cells (PBMCs), monocyte-derived macrophages and dendritic cells (moDCs).
Methods: Human PBMCs, macrophages and moDCs were stimulated with different COVID-19 vaccines, and the expression of interferon (IFN-λ1, IFN-α1), pro-inflammatory (IL-1β, IL-6, IL-8, IL-18, CXCL-4, CXCL-10, TNF-α) and Th1-type cytokine mRNAs (IL-2, IFN-γ) were analyzed by qPCR.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!